Zydus Lifesciences Limited has informed the Exchange about General Updates

Listed Co AcquisitionStrategic Transactions View source PDF Explain this filing

ZYDUSLIFE · price

Loading chart…

▲ positive · ▼ negative · ● neutral filings · teal = economic event · numbered = multiple that day (click to pick). Times IST.

Price reactionminutes from the announcement price · days from the prior close

+0.8%Reaction day

₹925.25

prior close

₹934.95

announcement price

After-mkt

timing

Nifty 100market · index membership as recorded later (tracked since Jun 2026)+0.3%+0.4% vs market

Pharmaceuticals peers, median of 150sector-0.1%+0.9% vs sector

On the reaction day the stock moved 0.4 pts more than Nifty 100 and 0.9 pts more than its Pharmaceuticals peers, over the same two closes: a difference in percentage points, not a measure of what the filing did.

Minutes after the announcementfrom the announcement price · no benchmark

Stock

+0.0

10m

+0.6

15m

+0.5

30m

-0.7

Sessions after the filingfrom the prior close

StockMarketvs marketSectorvs sector

Reaction day

+0.8+0.3+0.4-0.1+0.9

Next day

+3.2+0.8+2.3-0.0+3.2

+3.7+1.9+1.8-0.0+3.7

+5.3+2.5+2.8+0.4+4.9

+6.0+2.5+3.6+1.2+4.8

+5.8+2.6+3.2+1.6+4.1

+5.3+0.7+4.6+1.3+4.0

15d

+5.3+2.6+2.6-1.2+6.5

+8.1+3.6+4.5+1.2+6.8

+3.7+0.7+3.0-0.1+3.8

+9.5+0.8+8.7-2.6+12.1

UpDownMarket · Nifty 100Sector · Pharmaceuticals peers, median of 150Pending

Minute windows have no benchmark: there is no intraday index history to compare against.

AI summary

Zydus Lifesciences, through its wholly owned US subsidiary Zynext Ventures USA LLC, has signed a Securities Purchase Agreement to acquire a 5.9% stake in Agenus Inc., a US-based clinical-stage immuno-oncology company. The deal involves buying 2,133,333 shares at USD 7.50 per share, totalling around USD 16 million in cash. Agenus is developing next-generation cancer immunotherapies, with its lead BOT/BAL programme showing clinical activity across nine cancer types in over 1,200 patients. Agenus had a turnover of USD 103.46 million in CY2024. The transaction is subject to US regulatory approvals (Hart-Scott-Rodino, CFIUS) and is expected to close within 60 days.

Likely market impact

This is a relatively small strategic investment (about USD 16 million) for Zydus, aimed at strengthening its immuno-oncology pipeline and global reach. Minor impact on near-term financials given the small deal size, but could create long-term value if BOT/BAL therapy succeeds in clinical trials.